Evaluation of plasma-free endocannabinoids and their congeners in abstinent cocaine addicts seeking outpatient treatment: impact of psychiatric co-morbidity
Cocaine is associated with serious health problems including psychiatric co‐morbidity. There is a need for the identification of biomarkers for the stratification of cocaine‐addicted subjects. Several studies have evaluated circulating endocannabinoid‐related lipids as biomarkers of inflammatory, me...
Saved in:
Published in | Addiction biology Vol. 18; no. 6; pp. 955 - 969 |
---|---|
Main Authors | , , , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
Blackwell Publishing Ltd
01.11.2013
John Wiley & Sons, Inc |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Cocaine is associated with serious health problems including psychiatric co‐morbidity. There is a need for the identification of biomarkers for the stratification of cocaine‐addicted subjects. Several studies have evaluated circulating endocannabinoid‐related lipids as biomarkers of inflammatory, metabolic and mental disorders. However, little is known in substance use disorders. This study characterizes both free N‐acyl‐ethanolamines (NAEs) and 2‐acyl‐glycerols in abstinent cocaine addicts from outpatient treatment programs who were diagnosed with cocaine use disorder (CUD; n = 88), and age‐/gender‐/body mass‐matched healthy control volunteers (n = 46). Substance and mental disorders that commonly occur with substance abuse were assessed by the semi‐structured interview ‘Psychiatric Research Interview for Substance and Mental Diseases' according to the ‘Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision’ (DSM‐IV‐TR) and plasma‐free acyl derivatives were quantified by a liquid chromatography‐tandem mass spectrometry system. The results indicate that plasma acyl derivatives are altered in abstinent cocaine‐addicted subjects with CUD (CUD subjects). While NAEs were found to be increased, 2‐acyl‐glycerols were decreased in CUD subjects compared with controls. Multivariate predictive models based on these lipids as explanatory variables were developed to distinguish CUD subjects from controls providing high discriminatory power. However, these alterations were not influenced by the DSM‐IV‐TR criteria for cocaine abuse and dependence as cocaine trait severity measure. In contrast, we observed that some free acyl derivatives in CUD subjects were found to be affected by the diagnosis of some co‐morbid psychiatric disorders. Thus, we found that the monounsaturated NAEs were significantly elevated in CUD subjects diagnosed with mood [N‐oleoyl‐ethanolamine and N‐palmitoleoyl‐ethanolamine (POEA)] and anxiety (POEA) disorders compared with non‐co‐morbid CUD subjects. Interestingly, the coexistence of alcohol use disorders did not influence the circulating levels of these free acyl derivatives. In summary, we have identified plasma‐free acyl derivatives that might serve as reliable biomarkers for CUD. Furthermore, we found that monounsaturated NAE levels are also enhanced by co‐morbid mood and anxiety disorders in cocaine addicts. These findings open the way for the development of new strategies for cocaine addiction diagnosis and treatment. |
---|---|
AbstractList | Cocaine is associated with serious health problems including psychiatric co-morbidity. There is a need for the identification of biomarkers for the stratification of cocaine-addicted subjects. Several studies have evaluated circulating endocannabinoid-related lipids as biomarkers of inflammatory, metabolic and mental disorders. However, little is known in substance use disorders. This study characterizes both free N-acyl-ethanolamines (NAEs) and 2-acyl-glycerols in abstinent cocaine addicts from outpatient treatment programs who were diagnosed with cocaine use disorder (CUD; n = 88), and age-/gender-/body mass-matched healthy control volunteers (n = 46). Substance and mental disorders that commonly occur with substance abuse were assessed by the semi-structured interview 'Psychiatric Research Interview for Substance and Mental Diseases' according to the 'Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision' (DSM-IV-TR) and plasma-free acyl derivatives were quantified by a liquid chromatography-tandem mass spectrometry system. The results indicate that plasma acyl derivatives are altered in abstinent cocaine-addicted subjects with CUD (CUD subjects). While NAEs were found to be increased, 2-acyl-glycerols were decreased in CUD subjects compared with controls. Multivariate predictive models based on these lipids as explanatory variables were developed to distinguish CUD subjects from controls providing high discriminatory power. However, these alterations were not influenced by the DSM-IV-TR criteria for cocaine abuse and dependence as cocaine trait severity measure. In contrast, we observed that some free acyl derivatives in CUD subjects were found to be affected by the diagnosis of some co-morbid psychiatric disorders. Thus, we found that the monounsaturated NAEs were significantly elevated in CUD subjects diagnosed with mood [N-oleoyl-ethanolamine and N-palmitoleoyl-ethanolamine (POEA)] and anxiety (POEA) disorders compared with non-co-morbid CUD subjects. Interestingly, the coexistence of alcohol use disorders did not influence the circulating levels of these free acyl derivatives. In summary, we have identified plasma-free acyl derivatives that might serve as reliable biomarkers for CUD. Furthermore, we found that monounsaturated NAE levels are also enhanced by co-morbid mood and anxiety disorders in cocaine addicts. These findings open the way for the development of new strategies for cocaine addiction diagnosis and treatment.Cocaine is associated with serious health problems including psychiatric co-morbidity. There is a need for the identification of biomarkers for the stratification of cocaine-addicted subjects. Several studies have evaluated circulating endocannabinoid-related lipids as biomarkers of inflammatory, metabolic and mental disorders. However, little is known in substance use disorders. This study characterizes both free N-acyl-ethanolamines (NAEs) and 2-acyl-glycerols in abstinent cocaine addicts from outpatient treatment programs who were diagnosed with cocaine use disorder (CUD; n = 88), and age-/gender-/body mass-matched healthy control volunteers (n = 46). Substance and mental disorders that commonly occur with substance abuse were assessed by the semi-structured interview 'Psychiatric Research Interview for Substance and Mental Diseases' according to the 'Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision' (DSM-IV-TR) and plasma-free acyl derivatives were quantified by a liquid chromatography-tandem mass spectrometry system. The results indicate that plasma acyl derivatives are altered in abstinent cocaine-addicted subjects with CUD (CUD subjects). While NAEs were found to be increased, 2-acyl-glycerols were decreased in CUD subjects compared with controls. Multivariate predictive models based on these lipids as explanatory variables were developed to distinguish CUD subjects from controls providing high discriminatory power. However, these alterations were not influenced by the DSM-IV-TR criteria for cocaine abuse and dependence as cocaine trait severity measure. In contrast, we observed that some free acyl derivatives in CUD subjects were found to be affected by the diagnosis of some co-morbid psychiatric disorders. Thus, we found that the monounsaturated NAEs were significantly elevated in CUD subjects diagnosed with mood [N-oleoyl-ethanolamine and N-palmitoleoyl-ethanolamine (POEA)] and anxiety (POEA) disorders compared with non-co-morbid CUD subjects. Interestingly, the coexistence of alcohol use disorders did not influence the circulating levels of these free acyl derivatives. In summary, we have identified plasma-free acyl derivatives that might serve as reliable biomarkers for CUD. Furthermore, we found that monounsaturated NAE levels are also enhanced by co-morbid mood and anxiety disorders in cocaine addicts. These findings open the way for the development of new strategies for cocaine addiction diagnosis and treatment. Cocaine is associated with serious health problems including psychiatric co‐morbidity. There is a need for the identification of biomarkers for the stratification of cocaine‐addicted subjects. Several studies have evaluated circulating endocannabinoid‐related lipids as biomarkers of inflammatory, metabolic and mental disorders. However, little is known in substance use disorders. This study characterizes both free N‐acyl‐ethanolamines (NAEs) and 2‐acyl‐glycerols in abstinent cocaine addicts from outpatient treatment programs who were diagnosed with cocaine use disorder (CUD; n = 88), and age‐/gender‐/body mass‐matched healthy control volunteers (n = 46). Substance and mental disorders that commonly occur with substance abuse were assessed by the semi‐structured interview ‘Psychiatric Research Interview for Substance and Mental Diseases' according to the ‘Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision’ (DSM‐IV‐TR) and plasma‐free acyl derivatives were quantified by a liquid chromatography‐tandem mass spectrometry system. The results indicate that plasma acyl derivatives are altered in abstinent cocaine‐addicted subjects with CUD (CUD subjects). While NAEs were found to be increased, 2‐acyl‐glycerols were decreased in CUD subjects compared with controls. Multivariate predictive models based on these lipids as explanatory variables were developed to distinguish CUD subjects from controls providing high discriminatory power. However, these alterations were not influenced by the DSM‐IV‐TR criteria for cocaine abuse and dependence as cocaine trait severity measure. In contrast, we observed that some free acyl derivatives in CUD subjects were found to be affected by the diagnosis of some co‐morbid psychiatric disorders. Thus, we found that the monounsaturated NAEs were significantly elevated in CUD subjects diagnosed with mood [N‐oleoyl‐ethanolamine and N‐palmitoleoyl‐ethanolamine (POEA)] and anxiety (POEA) disorders compared with non‐co‐morbid CUD subjects. Interestingly, the coexistence of alcohol use disorders did not influence the circulating levels of these free acyl derivatives. In summary, we have identified plasma‐free acyl derivatives that might serve as reliable biomarkers for CUD. Furthermore, we found that monounsaturated NAE levels are also enhanced by co‐morbid mood and anxiety disorders in cocaine addicts. These findings open the way for the development of new strategies for cocaine addiction diagnosis and treatment. Cocaine is associated with serious health problems including psychiatric co-morbidity. There is a need for the identification of biomarkers for the stratification of cocaine-addicted subjects. Several studies have evaluated circulating endocannabinoid-related lipids as biomarkers of inflammatory, metabolic and mental disorders. However, little is known in substance use disorders. This study characterizes both free N-acyl-ethanolamines (NAEs) and 2-acyl-glycerols in abstinent cocaine addicts from outpatient treatment programs who were diagnosed with cocaine use disorder (CUD; n=88), and age-/gender-/body mass-matched healthy control volunteers (n=46). Substance and mental disorders that commonly occur with substance abuse were assessed by the semi-structured interview 'Psychiatric Research Interview for Substance and Mental Diseases' according to the 'Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision' (DSM-IV-TR) and plasma-free acyl derivatives were quantified by a liquid chromatography-tandem mass spectrometry system. The results indicate that plasma acyl derivatives are altered in abstinent cocaine-addicted subjects with CUD (CUD subjects). While NAEs were found to be increased, 2-acyl-glycerols were decreased in CUD subjects compared with controls. Multivariate predictive models based on these lipids as explanatory variables were developed to distinguish CUD subjects from controls providing high discriminatory power. However, these alterations were not influenced by the DSM-IV-TR criteria for cocaine abuse and dependence as cocaine trait severity measure. In contrast, we observed that some free acyl derivatives in CUD subjects were found to be affected by the diagnosis of some co-morbid psychiatric disorders. Thus, we found that the monounsaturated NAEs were significantly elevated in CUD subjects diagnosed with mood [N-oleoyl-ethanolamine and N-palmitoleoyl-ethanolamine (POEA)] and anxiety (POEA) disorders compared with non-co-morbid CUD subjects. Interestingly, the coexistence of alcohol use disorders did not influence the circulating levels of these free acyl derivatives. In summary, we have identified plasma-free acyl derivatives that might serve as reliable biomarkers for CUD. Furthermore, we found that monounsaturated NAE levels are also enhanced by co-morbid mood and anxiety disorders in cocaine addicts. These findings open the way for the development of new strategies for cocaine addiction diagnosis and treatment. [PUBLICATION ABSTRACT] |
Author | Campos-Cloute, Rafael Torrens, Marta Blanco, Eduardo Vergara-Moragues, Esperanza Romero-Cuevas, Miguel Pedraz, María Pastor, Antoni Rivera, Patricia Serrano, Antonia Ruiz, Juan Jesús Gornemann, Isolde Araos, Pedro Pavón, Francisco Javier Suárez, Juan Rodríguez de Fonseca, Fernando Pujadas, Mitona Calado, Montserrat de la Torre, Rafael |
Author_xml | – sequence: 1 givenname: Francisco Javier surname: Pavón fullname: Pavón, Francisco Javier organization: Unidad de Gestión Clínica de Salud Mental, Instituto de Investigación Biomédica de Málaga (IBIMA), Hospital Regional Universitario de Málaga, Spain – sequence: 2 givenname: Pedro surname: Araos fullname: Araos, Pedro organization: Unidad de Gestión Clínica de Salud Mental, Instituto de Investigación Biomédica de Málaga (IBIMA), Hospital Regional Universitario de Málaga, Spain – sequence: 3 givenname: Antoni surname: Pastor fullname: Pastor, Antoni organization: Neurosciences Programme, Institut Hospital del Mar d'Investigacions Mediques (IMIM), Spain – sequence: 4 givenname: Montserrat surname: Calado fullname: Calado, Montserrat organization: Unidad de Gestión Clínica de Salud Mental, Instituto de Investigación Biomédica de Málaga (IBIMA), Hospital Regional Universitario de Málaga, Spain – sequence: 5 givenname: María surname: Pedraz fullname: Pedraz, María organization: Unidad de Gestión Clínica de Salud Mental, Instituto de Investigación Biomédica de Málaga (IBIMA), Hospital Regional Universitario de Málaga, Spain – sequence: 6 givenname: Rafael surname: Campos-Cloute fullname: Campos-Cloute, Rafael organization: Centro Comarcal de Drogodependencias, Spain – sequence: 7 givenname: Juan Jesús surname: Ruiz fullname: Ruiz, Juan Jesús organization: Centro De Tratamiento Ambulatorio, Spain – sequence: 8 givenname: Antonia surname: Serrano fullname: Serrano, Antonia organization: Unidad de Gestión Clínica de Salud Mental, Instituto de Investigación Biomédica de Málaga (IBIMA), Hospital Regional Universitario de Málaga, Spain – sequence: 9 givenname: Eduardo surname: Blanco fullname: Blanco, Eduardo organization: Unidad de Gestión Clínica de Salud Mental, Instituto de Investigación Biomédica de Málaga (IBIMA), Hospital Regional Universitario de Málaga, Spain – sequence: 10 givenname: Patricia surname: Rivera fullname: Rivera, Patricia organization: Unidad de Gestión Clínica de Salud Mental, Instituto de Investigación Biomédica de Málaga (IBIMA), Hospital Regional Universitario de Málaga, Spain – sequence: 11 givenname: Juan surname: Suárez fullname: Suárez, Juan organization: Unidad de Gestión Clínica de Salud Mental, Instituto de Investigación Biomédica de Málaga (IBIMA), Hospital Regional Universitario de Málaga, Spain – sequence: 12 givenname: Miguel surname: Romero-Cuevas fullname: Romero-Cuevas, Miguel organization: Unidad de Gestión Clínica de Salud Mental, Instituto de Investigación Biomédica de Málaga (IBIMA), Hospital Regional Universitario de Málaga, Spain – sequence: 13 givenname: Mitona surname: Pujadas fullname: Pujadas, Mitona organization: Neurosciences Programme, Institut Hospital del Mar d'Investigacions Mediques (IMIM), Spain – sequence: 14 givenname: Esperanza surname: Vergara-Moragues fullname: Vergara-Moragues, Esperanza organization: Grupo de Investigación de Neuropsicología y Psiconeuroinmunología Clínica, Universidad de Granada, Spain – sequence: 15 givenname: Isolde surname: Gornemann fullname: Gornemann, Isolde organization: Unidad de Gestión Clínica de Salud Mental, Instituto de Investigación Biomédica de Málaga (IBIMA), Hospital Regional Universitario de Málaga, Spain – sequence: 16 givenname: Marta surname: Torrens fullname: Torrens, Marta organization: Neurosciences Programme, Institut Hospital del Mar d'Investigacions Mediques (IMIM), Spain – sequence: 17 givenname: Rafael surname: de la Torre fullname: de la Torre, Rafael organization: Neurosciences Programme, Institut Hospital del Mar d'Investigacions Mediques (IMIM), Spain – sequence: 18 givenname: Fernando surname: Rodríguez de Fonseca fullname: Rodríguez de Fonseca, Fernando email: fernando.rodriguez@fundacionimabis.org organization: Unidad de Gestión Clínica de Salud Mental, Instituto de Investigación Biomédica de Málaga (IBIMA), Hospital Regional Universitario de Málaga, Spain |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/24283982$$D View this record in MEDLINE/PubMed |
BookMark | eNqNkc9u1DAQxi1URNuFAy-ALHHhktaO43iXW7u0BVQBlUA9WhNn0rpN7GA7tPsuPCzeP_TACV_8yf7NN5r5Dsme8w4Jec3ZEc_nGNrmiJecqWfkgIt6UfCasb21lrKoSy73yWGMd4zxUknxguyXVTkXi3l5QH6f_YJ-gmS9o76jYw9xgKILiBRd6w04B4113raRgmtpukUbqPHuBh2GSK2j0MRkHbqUnw1kRaFtrUmRRsR7626on9KYW6yRFBDSkNV7aocRTNp0jStzayEFa7JHMfjQ2Nam1UvyvIM-4qvdPSM_zs--Lz8Wl18vPi1PLgsrJFOF4BKAmdrIPDxy4EKh6CpUHZetRDlnvFGLhWJ1BgyqEk1TNV1tADjHiokZebf1HYP_OWFMerDRYN-DQz9FzatFWVfV_L_QulR55XnPM_L2H_TOT8HlQdbUvFY7wzc7amoGbPUY7ABhpf9GlIHjLfBge1w9_XOm19nrnL3eZK9PPpxuRK4othU2Jnx8qoBwr2sllNTXXy708uqzOP_Gr_S1-AMOgLO0 |
ContentType | Journal Article |
Copyright | 2013 Society for the Study of Addiction 2013 Society for the Study of Addiction. |
Copyright_xml | – notice: 2013 Society for the Study of Addiction – notice: 2013 Society for the Study of Addiction. |
DBID | BSCLL CGR CUY CVF ECM EIF NPM 7QG 7T5 7TM H94 7X8 7TK |
DOI | 10.1111/adb.12107 |
DatabaseName | Istex Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Animal Behavior Abstracts Immunology Abstracts Nucleic Acids Abstracts AIDS and Cancer Research Abstracts MEDLINE - Academic Neurosciences Abstracts |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) AIDS and Cancer Research Abstracts Immunology Abstracts Animal Behavior Abstracts Nucleic Acids Abstracts MEDLINE - Academic Neurosciences Abstracts |
DatabaseTitleList | MEDLINE - Academic MEDLINE Neurosciences Abstracts AIDS and Cancer Research Abstracts |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Social Welfare & Social Work |
EISSN | 1369-1600 |
EndPage | 969 |
ExternalDocumentID | 3158447151 24283982 ADB12107 ark_67375_WNG_CQJ3FP1Q_W |
Genre | article Research Support, Non-U.S. Gov't Journal Article |
GrantInformation_xml | – fundername: Plan Nacional sobre Drogas funderid: 049/2009 – fundername: Consejería de Economía, Innovación y Ciencia, Junta de Andalucía UE‐FEDER funderid: CTS‐433 – fundername: Consejería de Salud, Junta de Andalucía funderid: SAS 111224 – fundername: Instituto de Salud Carlos III, Red de Trastornos Adictivos UE‐FEDER 2006 and 2012 funderid: RD06/0001/0000; RD12/0028/0001; RD06/0001/1009; RD12/0028/0009 |
GroupedDBID | --- .3N .GA .Y3 05W 0R~ 1OB 1OC 23M 24P 31~ 33P 36B 3SF 3V. 4.4 50Y 50Z 52M 52O 52T 52U 52V 52W 53G 5GY 5HH 5RE 5VS 702 7PT 7X7 8-0 8-1 8-3 8-4 8-5 88E 8FE 8FH 8FI 8FJ 930 A01 A03 AAESR AAEVG AAHHS AANLZ AAONW AASGY AAWTL AAXRX AAZKR ABCUV ABDBF ABIVO ABPVW ABUWG ABXGK ACAHQ ACBWZ ACCFJ ACCZN ACGEJ ACGFS ACGOF ACMXC ACPOU ACPRK ACXBN ACXQS ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADOZA ADPDF ADXAS ADXPE ADZMN ADZOD AEEZP AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFGKR AFKRA AFPWT AHEFC AIACR AIURR AIWBW AJBDE AJWEG ALAGY ALIPV ALMA_UNASSIGNED_HOLDINGS ALUQN AMBMR AMYDB ASPBG ATUGU AVWKF AZBYB AZFZN AZQEC AZVAB BAFTC BBNVY BDRZF BENPR BFHJK BHBCM BHPHI BMXJE BPHCQ BROTX BRXPI BSCLL BVXVI C45 CAG CCPQU COF CS3 D-6 D-7 D-E D-F DC6 DCZOG DPXWK DRFUL DRMAN DRSTM DUUFO DWQXO EAD EAP EAS EBD EBS EJD EMB EMK EMOBN EPT ESX F00 F01 F04 F21 F5P FEDTE FUBAC FYUFA FZ0 G-S G.N GNUQQ GODZA H.X HCIFZ HF~ HMCUK HVGLF HZ~ KBYEO LATKE LEEKS LH4 LITHE LK8 LOXES LP6 LP7 LUTES LW6 LYRES M1P M2M M7P MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 NF~ O66 O9- OIG OVD OVEED P2P P2W P2X P2Z P4B P4D PALCI PQQKQ PROAC PSQYO PSYQQ Q.N QB0 Q~Q R.K RIWAO RJQFR ROL RPM RX1 SAMSI SUPJJ SV3 TEORI TUS UB1 UKHRP W8V W99 WBKPD WIH WIJ WIK WNSPC WOHZO WUP WXSBR WYISQ ZZTAW ~IA ~WT AAFWJ AAMMB AANHP AAYCA ACCMX ACRPL ACUHS ACYXJ ADNMO AEFGJ AFPKN AFWVQ AGQPQ AGXDD AIDQK AIDYY GROUPED_DOAJ PHGZM PHGZT PJZUB PPXIY PQGLB CGR CUY CVF ECM EIF NPM 7QG 7T5 7TM H94 7X8 7TK |
ID | FETCH-LOGICAL-i3507-315aa0c6c5136e1a137e3f4e7f15d5e5801b799706513ce72ecb4bf6caa11e403 |
ISSN | 1355-6215 1369-1600 |
IngestDate | Fri Jul 11 09:29:50 EDT 2025 Thu Jul 10 22:19:16 EDT 2025 Fri Jul 25 12:06:46 EDT 2025 Mon Jul 21 05:55:45 EDT 2025 Wed Aug 20 07:27:58 EDT 2025 Wed Oct 30 09:52:38 EDT 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 6 |
Keywords | endocannabinoid dependence DSM-IV-TR psychiatric co-morbidity Abuse cocaine |
Language | English |
License | 2013 Society for the Study of Addiction. |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-i3507-315aa0c6c5136e1a137e3f4e7f15d5e5801b799706513ce72ecb4bf6caa11e403 |
Notes | istex:8A0688B5B390DBF5EF8C8D0F6709F5436F18D2E4 ArticleID:ADB12107 Consejería de Economía, Innovación y Ciencia, Junta de Andalucía UE-FEDER - No. CTS-433 Consejería de Salud, Junta de Andalucía - No. SAS 111224 Figure S1 Correlation analyses between plasma levels of NAEs and 2-acyl-glycerols, and DSM-IV criteria for cocaine abuse and dependence in CUD-subjects Figure S2 Plasma levels of NAEs and 2-acyl-glycerols in CUD-subjects with comorbid alcohol use disorders Table S1 Binary logistic regression models for distinguishing cocaine use disorders (CUD) with the plasma concentrations of NAEs and polyunsaturated 2-acyl-glycerols Instituto de Salud Carlos III, Red de Trastornos Adictivos UE-FEDER 2006 and 2012 - No. RD06/0001/0000; No. RD12/0028/0001; No. RD06/0001/1009; No. RD12/0028/0009 ark:/67375/WNG-CQJ3FP1Q-W Plan Nacional sobre Drogas - No. 049/2009 ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 14 ObjectType-Article-1 ObjectType-Feature-2 content type line 23 |
PMID | 24283982 |
PQID | 1468674840 |
PQPubID | 2028711 |
PageCount | 15 |
ParticipantIDs | proquest_miscellaneous_1492644840 proquest_miscellaneous_1462762175 proquest_journals_1468674840 pubmed_primary_24283982 wiley_primary_10_1111_adb_12107_ADB12107 istex_primary_ark_67375_WNG_CQJ3FP1Q_W |
PublicationCentury | 2000 |
PublicationDate | 2013-11 November 2013 2013-Nov 20131101 |
PublicationDateYYYYMMDD | 2013-11-01 |
PublicationDate_xml | – month: 11 year: 2013 text: 2013-11 |
PublicationDecade | 2010 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States – name: Leeds |
PublicationTitle | Addiction biology |
PublicationTitleAlternate | Addiction Biology |
PublicationYear | 2013 |
Publisher | Blackwell Publishing Ltd John Wiley & Sons, Inc |
Publisher_xml | – name: Blackwell Publishing Ltd – name: John Wiley & Sons, Inc |
References | Hasin DS, Fenton MC, Beseler C, Park JY, Wall MM (2012) Analyses related to the development of DSM-5 criteria for substance use related disorders: 2. Proposed DSM-5 criteria for alcohol, cannabis, cocaine and heroin disorders in 663 substance abuse patients. Drug Alcohol Depend 122:28-37. LoVerme J, La Rana G, Russo R, Calignano A, Piomelli D (2005) The search for the palmitoylethanolamide receptor. Life Sci 77:1685-1698. Siegmund SV (2010) Role of the endocannabinoid system in alcoholic liver disease. Dig Dis 28:751-755. Razzouk D, Bordin IA, Jorge MR (2000) Comorbidity and global functioning (DSM-III-R Axis V) in a Brazilian sample of cocaine users. Subst Use Misuse 35:1307-1315. Wiskerke J, Pattij T, Schoffelmeer AN, De Vries TJ (2008) The role of CB1 receptors in psychostimulant addiction. Addict Biol 13:225-238. Editorial team (2010) The EMCDDA annual report 2010: the state of the drugs problem in Europe. Euro Surveill 15:19714. Matias I, Gatta-Cherifi B, Tabarin A, Clark S, Leste-Lasserre T, Marsicano G, Piazza PV, Cota D (2012) Endocannabinoids measurement in human saliva as potential biomarker of obesity. PLoS ONE 7:e42399. Mangieri RA, Hong KI, Piomelli D, Sinha R (2009) An endocannabinoid signal associated with desire for alcohol is suppressed in recently abstinent alcoholics. Psychopharmacology (Berl) 205:63-72. Ferrer B, Bermudez-Silva FJ, Bilbao A, Alvarez-Jaimes L, Sanchez-Vera I, Giuffrida A, Serrano A, Baixeras E, Khaturia S, Navarro M, Parsons LH, Piomelli D, Rodriguez de Fonseca F (2007) Regulation of brain anandamide by acute administration of ethanol. Biochem J 404:97-104. Potvin S, Kouassi E, Lipp O, Bouchard RH, Roy MA, Demers MF, Gendron A, Astarita G, Piomelli D, Stip E (2008) Endogenous cannabinoids in patients with schizophrenia and substance use disorder during quetiapine therapy. J Psychopharmacol 22:262-269. Riddle EL, Fleckenstein AE, Hanson GR (2005) Role of monoamine transporters in mediating psychostimulant effects. AAPS J 7:E847-E851. Torrens M, Serrano D, Astals M, Perez-Dominguez G, Martin-Santos R (2004) Diagnosing comorbid psychiatric disorders in substance abusers: validity of the Spanish versions of the Psychiatric Research Interview for Substance and Mental Disorders and the Structured Clinical Interview for DSM-IV. Am J Psychiatry 161:1231-1237. Gonzalez S, Cascio MG, Fernandez-Ruiz J, Fezza F, Di Marzo V, Ramos JA (2002) Changes in endocannabinoid contents in the brain of rats chronically exposed to nicotine, ethanol or cocaine. Brain Res 954:73-81. Sipe JC, Scott TM, Murray S, Harismendy O, Simon GM, Cravatt BF, Waalen J (2010) Biomarkers of endocannabinoid system activation in severe obesity. PLoS ONE 5:e8792. Vergara-Moragues E, Gonzalez-Saiz F, Lozano OM, Betanzos Espinosa P, Fernandez Calderon F, Bilbao-Acebos I, Perez Garcia M, Verdejo Garcia A (2012) Psychiatric comorbidity in cocaine users treated in therapeutic community: substance-induced versus independent disorders. Psychiatry Res 200:734-741. Jean-Gilles L, Feng S, Tench CR, Chapman V, Kendall DA, Barrett DA, Constantinescu CS (2009) Plasma endocannabinoid levels in multiple sclerosis. J Neurol Sci 287:212-215. Ben-Shahar O, Sacramento AD, Miller BW, Webb SM, Wroten MG, Silva HE, Caruana AL, Gordon EJ, Ploense KL, Ditzhazy J, Kippin TE, Szumlinski KK (2013) Deficits in ventromedial prefrontal cortex group 1 metabotropic glutamate receptor function mediate resistance to extinction during protracted withdrawal from an extensive history of cocaine self-administration. J Neurosci 33:495-506a. Schmid HH, Berdyshev EV (2002) Cannabinoid receptor-inactive N-acylethanolamines and other fatty acid amides: metabolism and function. Prostaglandins Leukot Essent Fatty Acids 66:363-376. Fernandez-Ruiz J, Hernandez M, Ramos JA (2010) Cannabinoid-dopamine interaction in the pathophysiology and treatment of CNS disorders. CNS Neurosci Ther 16:e72-e91. Feuerecker M, Hauer D, Gresset T, Lassas S, Kaufmann I, Vogeser M, Briegel J, Hornuss C, Chouker A, Schelling G (2012) Effect of an acute consumption of a moderate amount of ethanol on plasma endocannabinoid levels in humans. Alcohol Alcohol 47:226-232. Desfosses J, Stip E, Bentaleb LA, Lipp O, Chiasson JP, Furtos A, Venne K, Kouassi E, Potvin S (2012) Plasma endocannabinoid alterations in individuals with substance use disorder are dependent on the 'mirror effect' of schizophrenia. Front Psychiatry 3:85. Syed SK, Bui HH, Beavers LS, Farb TB, Ficorilli J, Chesterfield AK, Kuo MS, Bokvist K, Barrett DG, Efanov AM (2012) Regulation of GPR119 receptor activity with endocannabinoid-like lipids. Am J Physiol Endocrinol Metab 303:E1469-E1478. Morgello S, Holzer CE 3rd, Ryan E, Young C, Naseer M, Castellon SA, Frol AB, Atkinson JH, Gelman BB, Grant I, Singer EJ (2006) Interrater reliability of the Psychiatric Research Interview for Substance and Mental Disorders in an HIV-infected cohort: experience of the National NeuroAIDS Tissue Consortium. Int J Methods Psychiatr Res 15:131-138. Hill MN, Miller GE, Ho WS, Gorzalka BB, Hillard CJ (2008) Serum endocannabinoid content is altered in females with depressive disorders: a preliminary report. Pharmacopsychiatry 41:48-53. Quercioli A, Pataky Z, Vincenti G, Makoundou V, Di Marzo V, Montecucco F, Carballo S, Thomas A, Staub C, Steffens S, Seimbille Y, Golay A, Ratib O, Harsch E, Mach F, Schindler TH (2011) Elevated endocannabinoid plasma levels are associated with coronary circulatory dysfunction in obesity. Eur Heart J 32:1369-1378. Monteleone P, Matias I, Martiadis V, De Petrocellis L, Maj M, Di Marzo V (2005) Blood levels of the endocannabinoid anandamide are increased in anorexia nervosa and in binge-eating disorder, but not in bulimia nervosa. Neuropsychopharmacology 30:1216-1221. Hasin D, Samet S, Nunes E, Meydan J, Matseoane K, Waxman R (2006) Diagnosis of comorbid psychiatric disorders in substance users assessed with the Psychiatric Research Interview for Substance and Mental Disorders for DSM-IV. Am J Psychiatry 163:689-696. Schwarz E, Whitfield P, Nahnsen S, Wang L, Major H, Leweke FM, Koethe D, Lio P, Bahn S (2011) Alterations of primary fatty acid amides in serum of patients with severe mental illness. Front Biosci (Elite Ed) 3:308-314. Caille S, Alvarez-Jaimes L, Polis I, Stouffer DG, Parsons LH (2007) Specific alterations of extracellular endocannabinoid levels in the nucleus accumbens by ethanol, heroin, and cocaine self-administration. J Neurosci 27:3695-3702. Di Marzo V, Deutsch DG (1998) Biochemistry of the endogenous ligands of cannabinoid receptors. Neurobiol Dis 5:386-404. Plaza-Zabala A, Berrendero F, Suarez J, Bermudez-Silva FJ, Fernandez-Espejo E, Serrano A, Pavon FJ, Parsons LH, De Fonseca FR, Maldonado R, Robledo P (2010) Effects of the endogenous PPAR-alpha agonist, oleoylethanolamide on MDMA-induced cognitive deficits in mice. Synapse 64:379-389. De Marchi N, De Petrocellis L, Orlando P, Daniele F, Fezza F, Di Marzo V (2003) Endocannabinoid signalling in the blood of patients with schizophrenia. Lipids Health Dis 2:5. Schule C, Eser D, Baghai TC, Nothdurfter C, Kessler JS, Rupprecht R (2011) Neuroactive steroids in affective disorders: target for novel antidepressant or anxiolytic drugs? Neuroscience 191:55-77. Robins LN, Wing J, Wittchen HU, Helzer JE, Babor TF, Burke J, Farmer A, Jablenski A, Pickens R, Regier DA, Sartorius N, Towle LH (1988) The Composite International Diagnostic Interview-an epidemiologic instrument suitable for use in conjunction with different diagnostic systems and in different cultures. Arch Gen Psychiatry 45:1069-1077. Mascia P, Pistis M, Justinova Z, Panlilio LV, Luchicchi A, Lecca S, Scherma M, Fratta W, Fadda P, Barnes C, Redhi GH, Yasar S, Le Foll B, Tanda G, Piomelli D, Goldberg SR (2011) Blockade of nicotine reward and reinstatement by activation of alpha-type peroxisome proliferator-activated receptors. Biol Psychiatry 69:633-641. Pavón FJ, Serrano A, Romero-Cuevas M, Alonso M, Rodríguez de Fonseca F (2010) Oleoylethanolamide: a new player in peripheral control of energy metabolism. Therapeutic implications. Drug Discov Today Dis Mech 7:e175-e183. Deschaux O, Vendruscolo LF, Schlosburg JE, Diaz-Aguilar L, Yuan CJ, Sobieraj JC, George O, Koob GF, Mandyam CD (2012) Hippocampal neurogenesis protects against cocaine-primed relapse. Addict Biol. doi:10.1111/adb.12019. Karila L, Petit A, Lowenstein W, Reynaud M (2012) Diagnosis and consequences of cocaine addiction. Curr Med Chem 19:5612-5618. Diercks DB, Fonarow GC, Kirk JD, Jois-Bilowich P, Hollander JE, Weber JE, Wynne J, Mills RM, Yancy C, Peacock WF 4th (2008) Illicit stimulant use in a United States heart failure population presenting to the emergency department (from the Acute Decompensated Heart Failure National Registry Emergency Module). Am J Cardiol 102:1216-1219. Herrero MJ, Domingo-Salvany A, Torrens M, Brugal MT (2008) Psychiatric comorbidity in young cocaine users: induced versus independent disorders. Addiction 103:284-293. Kaufmann I, Schelling G, Eisner C, Richter HP, Krauseneck T, Vogeser M, Hauer D, Campolongo P, Chouker A, Beyer A, Thiel M (2008) Anandamide and neutrophil function in patients with fibromyalgia. Psychoneuroendocrinology 33:676-685. Serrano A, Parsons LH (2011) Endocannabinoid influence in drug reinforcement, dependence and addiction-related behaviors. Pharmacol Ther 132:215-241. Rivera P, Luque-Rojas MJ, Pastor A, Blanco E, Pavon FJ, Serrano A, Crespillo A, Vida M, Grondona JM, Cifuentes M, Bermudez-Silva FJ, de la Torre R, de Fonseca FR, Suarez J (2013a) Diet-dependent modulation of hippocampal expression of endocannabinoid signaling-related proteins in cannabinoid antagonist-treated obese rats. Eur J Neurosci 37:105-117. Rodriguez de Fonseca F, Del Arco I, Bermudez-Silva FJ, Bilbao A, Cippitelli A, Navarro M (2005) The endocannabinoid system: physiology and pharmacology. Alcohol Alcohol 40:2-14. Thomas MJ, Kalivas PW, Shaham Y (2008) Neuroplasticity in the mesolimbic dopamine system and cocaine addiction. Br J Pharmacol 154:327-342. Orio 2013b; 16 2010; 16 2010; 15 2012; 122 2009; 43 2012; 200 2004; 29 2010; 224 2004; 161 2002; 954 2012; 19 2008; 33 2011; 191 2008; 103 2008; 102 1998; 353 2013; 18 2010; 64 2010; 28 2003; 2 2006; 163 2009; 287 2005; 30 1988; 45 2010; 1801 2008; 22 2013; 110 2011; 69 2010; 5 2008; 154 2005; 77 2010; 7 2007; 27 2009; 205 2007; 404 2012 2013a; 37 2006; 15 2005; 40 2011; 32 2008; 13 1999; 2 2011; 3 2012; 303 2011; 132 2012; 3 2003; 425 2013; 33 2001; 7 2000; 35 2002; 66 2005; 7 2009; 8 2008; 41 2013 2012; 47 2012; 7 1998; 5 |
References_xml | – reference: Schmid HH, Berdyshev EV (2002) Cannabinoid receptor-inactive N-acylethanolamines and other fatty acid amides: metabolism and function. Prostaglandins Leukot Essent Fatty Acids 66:363-376. – reference: Bilbao A, Blanco E, Luque-Rojas MJ, Suarez J, Palomino A, Vida M, Araos P, Bermudez-Silva FJ, Fernandez-Espejo E, Spanagel R, Rodriguez de Fonseca F (2013) Oleoylethanolamide dose-dependently attenuates cocaine-induced behaviours through a PPARalpha receptor-independent mechanism. Addict Biol 18:78-87. – reference: Desfosses J, Stip E, Bentaleb LA, Lipp O, Chiasson JP, Furtos A, Venne K, Kouassi E, Potvin S (2012) Plasma endocannabinoid alterations in individuals with substance use disorder are dependent on the 'mirror effect' of schizophrenia. Front Psychiatry 3:85. – reference: Hasin D, Samet S, Nunes E, Meydan J, Matseoane K, Waxman R (2006) Diagnosis of comorbid psychiatric disorders in substance users assessed with the Psychiatric Research Interview for Substance and Mental Disorders for DSM-IV. Am J Psychiatry 163:689-696. – reference: Diercks DB, Fonarow GC, Kirk JD, Jois-Bilowich P, Hollander JE, Weber JE, Wynne J, Mills RM, Yancy C, Peacock WF 4th (2008) Illicit stimulant use in a United States heart failure population presenting to the emergency department (from the Acute Decompensated Heart Failure National Registry Emergency Module). Am J Cardiol 102:1216-1219. – reference: Schule C, Eser D, Baghai TC, Nothdurfter C, Kessler JS, Rupprecht R (2011) Neuroactive steroids in affective disorders: target for novel antidepressant or anxiolytic drugs? Neuroscience 191:55-77. – reference: Kaufmann I, Schelling G, Eisner C, Richter HP, Krauseneck T, Vogeser M, Hauer D, Campolongo P, Chouker A, Beyer A, Thiel M (2008) Anandamide and neutrophil function in patients with fibromyalgia. Psychoneuroendocrinology 33:676-685. – reference: Monteleone P, Matias I, Martiadis V, De Petrocellis L, Maj M, Di Marzo V (2005) Blood levels of the endocannabinoid anandamide are increased in anorexia nervosa and in binge-eating disorder, but not in bulimia nervosa. Neuropsychopharmacology 30:1216-1221. – reference: Torrens M, Serrano D, Astals M, Perez-Dominguez G, Martin-Santos R (2004) Diagnosing comorbid psychiatric disorders in substance abusers: validity of the Spanish versions of the Psychiatric Research Interview for Substance and Mental Disorders and the Structured Clinical Interview for DSM-IV. Am J Psychiatry 161:1231-1237. – reference: Fernandez-Ruiz J, Hernandez M, Ramos JA (2010) Cannabinoid-dopamine interaction in the pathophysiology and treatment of CNS disorders. CNS Neurosci Ther 16:e72-e91. – reference: Caille S, Alvarez-Jaimes L, Polis I, Stouffer DG, Parsons LH (2007) Specific alterations of extracellular endocannabinoid levels in the nucleus accumbens by ethanol, heroin, and cocaine self-administration. J Neurosci 27:3695-3702. – reference: Herrero MJ, Domingo-Salvany A, Torrens M, Brugal MT (2008) Psychiatric comorbidity in young cocaine users: induced versus independent disorders. Addiction 103:284-293. – reference: Siegmund SV (2010) Role of the endocannabinoid system in alcoholic liver disease. Dig Dis 28:751-755. – reference: Editorial team (2010) The EMCDDA annual report 2010: the state of the drugs problem in Europe. Euro Surveill 15:19714. – reference: Pavón FJ, Serrano A, Romero-Cuevas M, Alonso M, Rodríguez de Fonseca F (2010) Oleoylethanolamide: a new player in peripheral control of energy metabolism. Therapeutic implications. Drug Discov Today Dis Mech 7:e175-e183. – reference: Potvin S, Kouassi E, Lipp O, Bouchard RH, Roy MA, Demers MF, Gendron A, Astarita G, Piomelli D, Stip E (2008) Endogenous cannabinoids in patients with schizophrenia and substance use disorder during quetiapine therapy. J Psychopharmacol 22:262-269. – reference: Hill MN, Miller GE, Ho WS, Gorzalka BB, Hillard CJ (2008) Serum endocannabinoid content is altered in females with depressive disorders: a preliminary report. Pharmacopsychiatry 41:48-53. – reference: Matias I, Gatta-Cherifi B, Tabarin A, Clark S, Leste-Lasserre T, Marsicano G, Piazza PV, Cota D (2012) Endocannabinoids measurement in human saliva as potential biomarker of obesity. PLoS ONE 7:e42399. – reference: Ueda N, Tsuboi K, Uyama T (2010) Enzymological studies on the biosynthesis of N-acylethanolamines. Biochim Biophys Acta 1801:1274-1285. – reference: Orio L, Pavon FJ, Blanco E, Serrano A, Araos P, Pedraz M, Rivera P, Calado M, Suarez J, de Fonseca FR (2013) Lipid transmitter signaling as a new target for treatment of cocaine addiction: new roles for acylethanolamides and lysophosphatidic acid. Curr Pharm Des [Epub ahead of print]. – reference: Razzouk D, Bordin IA, Jorge MR (2000) Comorbidity and global functioning (DSM-III-R Axis V) in a Brazilian sample of cocaine users. Subst Use Misuse 35:1307-1315. – reference: De Vries TJ, Shaham Y, Homberg JR, Crombag H, Schuurman K, Dieben J, Vanderschuren LJ, Schoffelmeer AN (2001) A cannabinoid mechanism in relapse to cocaine seeking. Nat Med 7:1151-1154. – reference: Rivera P, Luque-Rojas MJ, Pastor A, Blanco E, Pavon FJ, Serrano A, Crespillo A, Vida M, Grondona JM, Cifuentes M, Bermudez-Silva FJ, de la Torre R, de Fonseca FR, Suarez J (2013a) Diet-dependent modulation of hippocampal expression of endocannabinoid signaling-related proteins in cannabinoid antagonist-treated obese rats. Eur J Neurosci 37:105-117. – reference: Fu J, Gaetani S, Oveisi F, Lo Verme J, Serrano A, Rodriguez De Fonseca F, Rosengarth A, Luecke H, Di Giacomo B, Tarzia G, Piomelli D (2003) Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-alpha. Nature 425:90-93. – reference: Vergara-Moragues E, Gonzalez-Saiz F, Lozano OM, Betanzos Espinosa P, Fernandez Calderon F, Bilbao-Acebos I, Perez Garcia M, Verdejo Garcia A (2012) Psychiatric comorbidity in cocaine users treated in therapeutic community: substance-induced versus independent disorders. Psychiatry Res 200:734-741. – reference: Ben-Shahar O, Sacramento AD, Miller BW, Webb SM, Wroten MG, Silva HE, Caruana AL, Gordon EJ, Ploense KL, Ditzhazy J, Kippin TE, Szumlinski KK (2013) Deficits in ventromedial prefrontal cortex group 1 metabotropic glutamate receptor function mediate resistance to extinction during protracted withdrawal from an extensive history of cocaine self-administration. J Neurosci 33:495-506a. – reference: Rivera P, Miguens M, Coria SM, Rubio L, Higuera-Matas A, Bermudez-Silva FJ, de Fonseca FR, Suarez J, Ambrosio E (2013b) Cocaine self-administration differentially modulates the expression of endogenous cannabinoid system-related proteins in the hippocampus of Lewis vs. Fischer 344 rats. Int J Neuropsychopharmacol 16:1277-1293. – reference: LoVerme J, La Rana G, Russo R, Calignano A, Piomelli D (2005) The search for the palmitoylethanolamide receptor. Life Sci 77:1685-1698. – reference: Riddle EL, Fleckenstein AE, Hanson GR (2005) Role of monoamine transporters in mediating psychostimulant effects. AAPS J 7:E847-E851. – reference: Ben-Shabat S, Fride E, Sheskin T, Tamiri T, Rhee MH, Vogel Z, Bisogno T, De Petrocellis L, Di Marzo V, Mechoulam R (1998) An entourage effect: inactive endogenous fatty acid glycerol esters enhance 2-arachidonoyl-glycerol cannabinoid activity. Eur J Pharmacol 353:23-31. – reference: Rodriguez de Fonseca F, Del Arco I, Bermudez-Silva FJ, Bilbao A, Cippitelli A, Navarro M (2005) The endocannabinoid system: physiology and pharmacology. Alcohol Alcohol 40:2-14. – reference: Sipe JC, Scott TM, Murray S, Harismendy O, Simon GM, Cravatt BF, Waalen J (2010) Biomarkers of endocannabinoid system activation in severe obesity. PLoS ONE 5:e8792. – reference: Hansen HS (2010) Palmitoylethanolamide and other anandamide congeners. Proposed role in the diseased brain. Exp Neurol 224:48-55. – reference: Hasin DS, Fenton MC, Beseler C, Park JY, Wall MM (2012) Analyses related to the development of DSM-5 criteria for substance use related disorders: 2. Proposed DSM-5 criteria for alcohol, cannabis, cocaine and heroin disorders in 663 substance abuse patients. Drug Alcohol Depend 122:28-37. – reference: Wiskerke J, Pattij T, Schoffelmeer AN, De Vries TJ (2008) The role of CB1 receptors in psychostimulant addiction. Addict Biol 13:225-238. – reference: Syed SK, Bui HH, Beavers LS, Farb TB, Ficorilli J, Chesterfield AK, Kuo MS, Bokvist K, Barrett DG, Efanov AM (2012) Regulation of GPR119 receptor activity with endocannabinoid-like lipids. Am J Physiol Endocrinol Metab 303:E1469-E1478. – reference: Ferrer B, Bermudez-Silva FJ, Bilbao A, Alvarez-Jaimes L, Sanchez-Vera I, Giuffrida A, Serrano A, Baixeras E, Khaturia S, Navarro M, Parsons LH, Piomelli D, Rodriguez de Fonseca F (2007) Regulation of brain anandamide by acute administration of ethanol. Biochem J 404:97-104. – reference: Feuerecker M, Hauer D, Gresset T, Lassas S, Kaufmann I, Vogeser M, Briegel J, Hornuss C, Chouker A, Schelling G (2012) Effect of an acute consumption of a moderate amount of ethanol on plasma endocannabinoid levels in humans. Alcohol Alcohol 47:226-232. – reference: Gonzalez S, Cascio MG, Fernandez-Ruiz J, Fezza F, Di Marzo V, Ramos JA (2002) Changes in endocannabinoid contents in the brain of rats chronically exposed to nicotine, ethanol or cocaine. Brain Res 954:73-81. – reference: De Marchi N, De Petrocellis L, Orlando P, Daniele F, Fezza F, Di Marzo V (2003) Endocannabinoid signalling in the blood of patients with schizophrenia. Lipids Health Dis 2:5. – reference: Plaza-Zabala A, Berrendero F, Suarez J, Bermudez-Silva FJ, Fernandez-Espejo E, Serrano A, Pavon FJ, Parsons LH, De Fonseca FR, Maldonado R, Robledo P (2010) Effects of the endogenous PPAR-alpha agonist, oleoylethanolamide on MDMA-induced cognitive deficits in mice. Synapse 64:379-389. – reference: Giuffrida A, Leweke FM, Gerth CW, Schreiber D, Koethe D, Faulhaber J, Klosterkotter J, Piomelli D (2004) Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms. Neuropsychopharmacology 29:2108-2114. – reference: Thomas MJ, Kalivas PW, Shaham Y (2008) Neuroplasticity in the mesolimbic dopamine system and cocaine addiction. Br J Pharmacol 154:327-342. – reference: Quercioli A, Pataky Z, Vincenti G, Makoundou V, Di Marzo V, Montecucco F, Carballo S, Thomas A, Staub C, Steffens S, Seimbille Y, Golay A, Ratib O, Harsch E, Mach F, Schindler TH (2011) Elevated endocannabinoid plasma levels are associated with coronary circulatory dysfunction in obesity. Eur Heart J 32:1369-1378. – reference: Koppel J, Bradshaw H, Goldberg TE, Khalili H, Marambaud P, Walker MJ, Pazos M, Gordon ML, Christen E, Davies P (2009) Endocannabinoids in Alzheimer's disease and their impact on normative cognitive performance: a case-control and cohort study. Lipids Health Dis 8:2. – reference: Di Marzo V, Deutsch DG (1998) Biochemistry of the endogenous ligands of cannabinoid receptors. Neurobiol Dis 5:386-404. – reference: Karila L, Petit A, Lowenstein W, Reynaud M (2012) Diagnosis and consequences of cocaine addiction. Curr Med Chem 19:5612-5618. – reference: Kaufmann I, Hauer D, Huge V, Vogeser M, Campolongo P, Chouker A, Thiel M, Schelling G (2009) Enhanced anandamide plasma levels in patients with complex regional pain syndrome following traumatic injury: a preliminary report. Eur Surg Res 43:325-329. – reference: Mascia P, Pistis M, Justinova Z, Panlilio LV, Luchicchi A, Lecca S, Scherma M, Fratta W, Fadda P, Barnes C, Redhi GH, Yasar S, Le Foll B, Tanda G, Piomelli D, Goldberg SR (2011) Blockade of nicotine reward and reinstatement by activation of alpha-type peroxisome proliferator-activated receptors. Biol Psychiatry 69:633-641. – reference: Schwarz E, Whitfield P, Nahnsen S, Wang L, Major H, Leweke FM, Koethe D, Lio P, Bahn S (2011) Alterations of primary fatty acid amides in serum of patients with severe mental illness. Front Biosci (Elite Ed) 3:308-314. – reference: Jean-Gilles L, Feng S, Tench CR, Chapman V, Kendall DA, Barrett DA, Constantinescu CS (2009) Plasma endocannabinoid levels in multiple sclerosis. J Neurol Sci 287:212-215. – reference: Liu HS, Chefer S, Lu H, Guillem K, Rea W, Kurup P, Yang Y, Peoples L, Stein EA (2013) Dorsolateral caudate nucleus differentiates cocaine from natural reward-associated contextual cues. Proc Natl Acad Sci U S A 110:4093-4098. – reference: Deschaux O, Vendruscolo LF, Schlosburg JE, Diaz-Aguilar L, Yuan CJ, Sobieraj JC, George O, Koob GF, Mandyam CD (2012) Hippocampal neurogenesis protects against cocaine-primed relapse. Addict Biol. doi:10.1111/adb.12019. – reference: Giuffrida A, Parsons LH, Kerr TM, Rodriguez de Fonseca F, Navarro M, Piomelli D (1999) Dopamine activation of endogenous cannabinoid signaling in dorsal striatum. Nat Neurosci 2:358-363. – reference: Morgello S, Holzer CE 3rd, Ryan E, Young C, Naseer M, Castellon SA, Frol AB, Atkinson JH, Gelman BB, Grant I, Singer EJ (2006) Interrater reliability of the Psychiatric Research Interview for Substance and Mental Disorders in an HIV-infected cohort: experience of the National NeuroAIDS Tissue Consortium. Int J Methods Psychiatr Res 15:131-138. – reference: Robins LN, Wing J, Wittchen HU, Helzer JE, Babor TF, Burke J, Farmer A, Jablenski A, Pickens R, Regier DA, Sartorius N, Towle LH (1988) The Composite International Diagnostic Interview-an epidemiologic instrument suitable for use in conjunction with different diagnostic systems and in different cultures. Arch Gen Psychiatry 45:1069-1077. – reference: Serrano A, Parsons LH (2011) Endocannabinoid influence in drug reinforcement, dependence and addiction-related behaviors. Pharmacol Ther 132:215-241. – reference: Mangieri RA, Hong KI, Piomelli D, Sinha R (2009) An endocannabinoid signal associated with desire for alcohol is suppressed in recently abstinent alcoholics. Psychopharmacology (Berl) 205:63-72. – volume: 32 start-page: 1369 year: 2011 end-page: 1378 article-title: Elevated endocannabinoid plasma levels are associated with coronary circulatory dysfunction in obesity publication-title: Eur Heart J – volume: 77 start-page: 1685 year: 2005 end-page: 1698 article-title: The search for the palmitoylethanolamide receptor publication-title: Life Sci – volume: 7 start-page: E847 year: 2005 end-page: E851 article-title: Role of monoamine transporters in mediating psychostimulant effects publication-title: AAPS J – volume: 33 start-page: 676 year: 2008 end-page: 685 article-title: Anandamide and neutrophil function in patients with fibromyalgia publication-title: Psychoneuroendocrinology – volume: 3 start-page: 308 year: 2011 end-page: 314 article-title: Alterations of primary fatty acid amides in serum of patients with severe mental illness publication-title: Front Biosci (Elite Ed) – volume: 103 start-page: 284 year: 2008 end-page: 293 article-title: Psychiatric comorbidity in young cocaine users: induced versus independent disorders publication-title: Addiction – volume: 954 start-page: 73 year: 2002 end-page: 81 article-title: Changes in endocannabinoid contents in the brain of rats chronically exposed to nicotine, ethanol or cocaine publication-title: Brain Res – volume: 15 start-page: 131 year: 2006 end-page: 138 article-title: Interrater reliability of the Psychiatric Research Interview for Substance and Mental Disorders in an HIV‐infected cohort: experience of the National NeuroAIDS Tissue Consortium publication-title: Int J Methods Psychiatr Res – volume: 41 start-page: 48 year: 2008 end-page: 53 article-title: Serum endocannabinoid content is altered in females with depressive disorders: a preliminary report publication-title: Pharmacopsychiatry – volume: 132 start-page: 215 year: 2011 end-page: 241 article-title: Endocannabinoid influence in drug reinforcement, dependence and addiction‐related behaviors publication-title: Pharmacol Ther – volume: 64 start-page: 379 year: 2010 end-page: 389 article-title: Effects of the endogenous PPAR‐alpha agonist, oleoylethanolamide on MDMA‐induced cognitive deficits in mice publication-title: Synapse – volume: 110 start-page: 4093 year: 2013 end-page: 4098 article-title: Dorsolateral caudate nucleus differentiates cocaine from natural reward‐associated contextual cues publication-title: Proc Natl Acad Sci U S A – year: 2013 article-title: Lipid transmitter signaling as a new target for treatment of cocaine addiction: new roles for acylethanolamides and lysophosphatidic acid publication-title: Curr Pharm Des – volume: 205 start-page: 63 year: 2009 end-page: 72 article-title: An endocannabinoid signal associated with desire for alcohol is suppressed in recently abstinent alcoholics publication-title: Psychopharmacology (Berl) – year: 2012 article-title: Hippocampal neurogenesis protects against cocaine‐primed relapse publication-title: Addict Biol – volume: 404 start-page: 97 year: 2007 end-page: 104 article-title: Regulation of brain anandamide by acute administration of ethanol publication-title: Biochem J – volume: 16 start-page: e72 year: 2010 end-page: e91 article-title: Cannabinoid‐dopamine interaction in the pathophysiology and treatment of CNS disorders publication-title: CNS Neurosci Ther – volume: 30 start-page: 1216 year: 2005 end-page: 1221 article-title: Blood levels of the endocannabinoid anandamide are increased in anorexia nervosa and in binge‐eating disorder, but not in bulimia nervosa publication-title: Neuropsychopharmacology – volume: 37 start-page: 105 year: 2013a end-page: 117 article-title: Diet‐dependent modulation of hippocampal expression of endocannabinoid signaling‐related proteins in cannabinoid antagonist‐treated obese rats publication-title: Eur J Neurosci – volume: 28 start-page: 751 year: 2010 end-page: 755 article-title: Role of the endocannabinoid system in alcoholic liver disease publication-title: Dig Dis – volume: 7 start-page: e175 year: 2010 end-page: e183 article-title: Oleoylethanolamide: a new player in peripheral control of energy metabolism. Therapeutic implications publication-title: Drug Discov Today Dis Mech – volume: 27 start-page: 3695 year: 2007 end-page: 3702 article-title: Specific alterations of extracellular endocannabinoid levels in the nucleus accumbens by ethanol, heroin, and cocaine self‐administration publication-title: J Neurosci – volume: 45 start-page: 1069 year: 1988 end-page: 1077 article-title: The Composite International Diagnostic Interview—an epidemiologic instrument suitable for use in conjunction with different diagnostic systems and in different cultures publication-title: Arch Gen Psychiatry – volume: 29 start-page: 2108 year: 2004 end-page: 2114 article-title: Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms publication-title: Neuropsychopharmacology – volume: 18 start-page: 78 year: 2013 end-page: 87 article-title: Oleoylethanolamide dose‐dependently attenuates cocaine‐induced behaviours through a PPARalpha receptor‐independent mechanism publication-title: Addict Biol – volume: 161 start-page: 1231 year: 2004 end-page: 1237 article-title: Diagnosing comorbid psychiatric disorders in substance abusers: validity of the Spanish versions of the Psychiatric Research Interview for Substance and Mental Disorders and the Structured Clinical Interview for DSM‐IV publication-title: Am J Psychiatry – volume: 7 start-page: 1151 year: 2001 end-page: 1154 article-title: A cannabinoid mechanism in relapse to cocaine seeking publication-title: Nat Med – volume: 224 start-page: 48 year: 2010 end-page: 55 article-title: Palmitoylethanolamide and other anandamide congeners. Proposed role in the diseased brain publication-title: Exp Neurol – volume: 19 start-page: 5612 year: 2012 end-page: 5618 article-title: Diagnosis and consequences of cocaine addiction publication-title: Curr Med Chem – volume: 5 start-page: 386 year: 1998 end-page: 404 article-title: Biochemistry of the endogenous ligands of cannabinoid receptors publication-title: Neurobiol Dis – volume: 7 start-page: e42399 year: 2012 article-title: Endocannabinoids measurement in human saliva as potential biomarker of obesity publication-title: PLoS ONE – volume: 69 start-page: 633 year: 2011 end-page: 641 article-title: Blockade of nicotine reward and reinstatement by activation of alpha‐type peroxisome proliferator‐activated receptors publication-title: Biol Psychiatry – volume: 154 start-page: 327 year: 2008 end-page: 342 article-title: Neuroplasticity in the mesolimbic dopamine system and cocaine addiction publication-title: Br J Pharmacol – volume: 33 start-page: 495 year: 2013 end-page: 506a article-title: Deficits in ventromedial prefrontal cortex group 1 metabotropic glutamate receptor function mediate resistance to extinction during protracted withdrawal from an extensive history of cocaine self‐administration publication-title: J Neurosci – volume: 353 start-page: 23 year: 1998 end-page: 31 article-title: An entourage effect: inactive endogenous fatty acid glycerol esters enhance 2‐arachidonoyl‐glycerol cannabinoid activity publication-title: Eur J Pharmacol – volume: 287 start-page: 212 year: 2009 end-page: 215 article-title: Plasma endocannabinoid levels in multiple sclerosis publication-title: J Neurol Sci – volume: 8 start-page: 2 year: 2009 article-title: Endocannabinoids in Alzheimer's disease and their impact on normative cognitive performance: a case‐control and cohort study publication-title: Lipids Health Dis – volume: 13 start-page: 225 year: 2008 end-page: 238 article-title: The role of CB1 receptors in psychostimulant addiction publication-title: Addict Biol – volume: 3 start-page: 85 year: 2012 article-title: Plasma endocannabinoid alterations in individuals with substance use disorder are dependent on the ‘mirror effect’ of schizophrenia publication-title: Front Psychiatry – volume: 22 start-page: 262 year: 2008 end-page: 269 article-title: Endogenous cannabinoids in patients with schizophrenia and substance use disorder during quetiapine therapy publication-title: J Psychopharmacol – volume: 15 start-page: 19714 year: 2010 article-title: The EMCDDA annual report 2010: the state of the drugs problem in Europe publication-title: Euro Surveill – volume: 43 start-page: 325 year: 2009 end-page: 329 article-title: Enhanced anandamide plasma levels in patients with complex regional pain syndrome following traumatic injury: a preliminary report publication-title: Eur Surg Res – volume: 303 start-page: E1469 year: 2012 end-page: E1478 article-title: Regulation of GPR119 receptor activity with endocannabinoid‐like lipids publication-title: Am J Physiol Endocrinol Metab – volume: 16 start-page: 1277 year: 2013b end-page: 1293 article-title: Cocaine self‐administration differentially modulates the expression of endogenous cannabinoid system‐related proteins in the hippocampus of Lewis vs. Fischer 344 rats publication-title: Int J Neuropsychopharmacol – volume: 35 start-page: 1307 year: 2000 end-page: 1315 article-title: Comorbidity and global functioning (DSM‐III‐R Axis V) in a Brazilian sample of cocaine users publication-title: Subst Use Misuse – volume: 47 start-page: 226 year: 2012 end-page: 232 article-title: Effect of an acute consumption of a moderate amount of ethanol on plasma endocannabinoid levels in humans publication-title: Alcohol Alcohol – volume: 122 start-page: 28 year: 2012 end-page: 37 article-title: Analyses related to the development of DSM‐5 criteria for substance use related disorders: 2. Proposed DSM‐5 criteria for alcohol, cannabis, cocaine and heroin disorders in 663 substance abuse patients publication-title: Drug Alcohol Depend – volume: 425 start-page: 90 year: 2003 end-page: 93 article-title: Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR‐alpha publication-title: Nature – volume: 1801 start-page: 1274 year: 2010 end-page: 1285 article-title: Enzymological studies on the biosynthesis of N‐acylethanolamines publication-title: Biochim Biophys Acta – volume: 163 start-page: 689 year: 2006 end-page: 696 article-title: Diagnosis of comorbid psychiatric disorders in substance users assessed with the Psychiatric Research Interview for Substance and Mental Disorders for DSM‐IV publication-title: Am J Psychiatry – volume: 40 start-page: 2 year: 2005 end-page: 14 article-title: The endocannabinoid system: physiology and pharmacology publication-title: Alcohol Alcohol – volume: 102 start-page: 1216 year: 2008 end-page: 1219 article-title: Illicit stimulant use in a United States heart failure population presenting to the emergency department (from the Acute Decompensated Heart Failure National Registry Emergency Module) publication-title: Am J Cardiol – volume: 200 start-page: 734 year: 2012 end-page: 741 article-title: Psychiatric comorbidity in cocaine users treated in therapeutic community: substance‐induced versus independent disorders publication-title: Psychiatry Res – volume: 5 start-page: e8792 year: 2010 article-title: Biomarkers of endocannabinoid system activation in severe obesity publication-title: PLoS ONE – volume: 2 start-page: 358 year: 1999 end-page: 363 article-title: Dopamine activation of endogenous cannabinoid signaling in dorsal striatum publication-title: Nat Neurosci – volume: 66 start-page: 363 year: 2002 end-page: 376 article-title: Cannabinoid receptor‐inactive N‐acylethanolamines and other fatty acid amides: metabolism and function publication-title: Prostaglandins Leukot Essent Fatty Acids – volume: 191 start-page: 55 year: 2011 end-page: 77 article-title: Neuroactive steroids in affective disorders: target for novel antidepressant or anxiolytic drugs? publication-title: Neuroscience – volume: 2 start-page: 5 year: 2003 article-title: Endocannabinoid signalling in the blood of patients with schizophrenia publication-title: Lipids Health Dis |
SSID | ssj0012753 |
Score | 2.226181 |
Snippet | Cocaine is associated with serious health problems including psychiatric co‐morbidity. There is a need for the identification of biomarkers for the... Cocaine is associated with serious health problems including psychiatric co-morbidity. There is a need for the identification of biomarkers for the... |
SourceID | proquest pubmed wiley istex |
SourceType | Aggregation Database Index Database Publisher |
StartPage | 955 |
SubjectTerms | Abuse Addiction Adult Ambulatory Care Analysis of Variance Area Under Curve Biomarkers - blood Case-Control Studies Chromatography, Liquid - methods cocaine Cocaine-Related Disorders - blood Cocaine-Related Disorders - epidemiology Cocaine-Related Disorders - rehabilitation Comorbidity dependence Diagnosis, Dual (Psychiatry) DSM-IV-TR endocannabinoid Endocannabinoids - blood Endocannabinoids - chemistry Ethanolamines - blood Ethanolamines - chemistry Fatty Acids, Monounsaturated - blood Female Glycerides - blood Glycerides - chemistry Humans Interview, Psychological Logistic Models Male Mental Disorders - blood Mental Disorders - epidemiology Patient Acceptance of Health Care psychiatric co-morbidity ROC Curve Severity of Illness Index Tandem Mass Spectrometry - methods |
Title | Evaluation of plasma-free endocannabinoids and their congeners in abstinent cocaine addicts seeking outpatient treatment: impact of psychiatric co-morbidity |
URI | https://api.istex.fr/ark:/67375/WNG-CQJ3FP1Q-W/fulltext.pdf https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fadb.12107 https://www.ncbi.nlm.nih.gov/pubmed/24283982 https://www.proquest.com/docview/1468674840 https://www.proquest.com/docview/1462762175 https://www.proquest.com/docview/1492644840 |
Volume | 18 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1fa9swEBdZ-rKXsf_Llg0NRhkUl_iP7HhvSdusBFZaaGnfjCzLxaS1h-OMsad9hH2EfbXtk-xOUuSkpKPbiwmSItvcz6c73e9OhLzzwCoGTyJ0Ah6Bg-KJwEnDnDluJL0s5r70h5ic_OkoPDwLphfsotP5tcJaWjTprvi2Ma_kf6QKbSBXzJL9B8naSaEBfoN84QoShuudZHxgS3Ur4jIYwtfcshfyWsodWWawWJUlBwe4KrL5kjBZ1Mg3v8Sa04oQy1P41EvkBYCC5Gh5ItEIiR5zKWeKGb1oTA3WlpyO2wltmqUlThcCZrHPcV3VaZEVzVr8eKRmxwc3VaDaUNYXjN2PfWtWi2Iuqp0pxwW8hSfX9MBjmdVV-995o3cfRngyctHGV654praEQYM1IBlA_epuh-ubtL9WQYN95ISeTgHdlaYtjB03HAw2a_UbKjpmbGW1j_VBMbcsJDxLsfyGPpd3vVi3HcRuHabLCu-PVdc9suWBJ-N1ydZovD-e2FCXp0ul2hcz5a-QbmbnBc8JP_qvm9ygda9KmUWnD8kD48_QkQbnI9KR5WPS10nf9Fxe5byWdJsuG6p69oT8bHFLq5xq3P7-_gMRS28ilgJiqUIstYilRUktYqlBLDWIpQaxtEUstYj9QDVe1X1bvMIccH-L1KfkbHJwunfomJNCnMJnaqOdcT4QoWCABely14-knwcyyl2WMcnADEujOMaQvusLGXlSpEGah4Jz15XBwH9GumVVyheERsINpAC7Os_jAMz_mPEs4F44HORpGGdBj2wrUSSfdTWYhNczJEdGLDk_-pjsnUz9ybF7kpz3SH8pq8TojDk62kM83icY9Mhb2w0aHcN0vJTVQo3xwEQBu_5vY2K1s4LzPNc4sA_kYQ3FeOj1yHsFDNux9PcBVomCVbIE58u7D31F7rffZZ90m3ohX4Nd3qRvDLL_AHz35sA |
linkProvider | EBSCOhost |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Evaluation+of+plasma%E2%80%90free+endocannabinoids+and+their+congeners+in+abstinent+cocaine+addicts+seeking+outpatient+treatment%3A+impact+of+psychiatric+co%E2%80%90morbidity&rft.jtitle=Addiction+biology&rft.au=Pav%C3%B3n%2C+Francisco+Javier&rft.au=Araos%2C+Pedro&rft.au=Pastor%2C+Antoni&rft.au=Calado%2C+Montserrat&rft.date=2013-11-01&rft.issn=1355-6215&rft.eissn=1369-1600&rft.volume=18&rft.issue=6&rft.spage=955&rft.epage=969&rft_id=info:doi/10.1111%2Fadb.12107&rft.externalDBID=10.1111%252Fadb.12107&rft.externalDocID=ADB12107 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1355-6215&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1355-6215&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1355-6215&client=summon |